论文部分内容阅读
目的探讨瑞舒伐他汀钙治疗原发性高胆固醇血症的临床疗效。方法选择2012年10月—2014年5月南京市浦口医院收治的64例原发性高胆固醇血症患者,随机分为对照组和观察组,各32例。对照组给予阿托伐他汀钙片治疗,观察组给予瑞舒伐他汀钙片治疗,比较两组的临床疗效、血脂水平及不良反应发生情况。结果观察组总有效率为90.62%,高于对照组的68.75%,差异有统计学意义(P<0.05)。治疗后观察组的总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平均低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论瑞舒伐他汀钙治疗原发性高胆固醇血症的临床疗效显著,可明显降低TC、TG、LDL-C水平,且不良反应少。
Objective To investigate the clinical efficacy of rosuvastatin calcium in the treatment of primary hypercholesterolemia. Methods Sixty-four patients with primary hypercholesterolemia who were treated in Nanjing Pukou Hospital from October 2012 to May 2014 were randomly divided into control group and observation group, with 32 cases in each group. The control group was given atorvastatin calcium tablets, and the observation group was given rosuvastatin calcium tablets. The clinical efficacy, blood lipid levels and adverse reactions in the two groups were compared. Results The total effective rate in the observation group was 90.62%, which was higher than that in the control group (68.75%), the difference was statistically significant (P <0.05). After treatment, the levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) in the observation group were lower than those in the control group, with statistical significance (P <0.05). The incidence of adverse reactions in the two groups, the difference was not statistically significant (P> 0.05). Conclusion Rosuvastatin calcium treatment of primary hypercholesterolemia clinical effect was significant, can significantly reduce the TC, TG, LDL-C levels, and less adverse reactions.